

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-11. (Cancelled)

12. (New) A human antibody, which specifically binds to human platelet membrane glycoprotein VI (GPVI) and does not induce human platelet aggregation independently, wherein the antibody consists of two heavy chains and two light chains.

13. (New) A human antibody, which specifically binds to human platelet membrane glycoprotein VI (GPVI) and suppresses collagen-mediated human platelet aggregation by in vivo administration, wherein the antibody consists of two heavy chains and two light chains.

14. (New) A human antibody, which specifically binds to human platelet membrane glycoprotein VI (GPVI) and has at least one of the following functions: specifically inhibiting binding of the GPVI on a human platelet to collagen; substantially minimizing presence of a functional GPVI on the platelet; or decreasing or deleting collagen-mediated aggregation of the human platelet by preliminarily contacting with the human platelet, wherein the antibody consists of two heavy chains and two light chains.

15. (New) A human antibody, which specifically binds to human platelet membrane glycoprotein VI (GPVI), suppresses collagen-mediated aggregation of a human platelet and does not induce human platelet aggregation independently, wherein the antibody consists of two heavy chains and two light chains.

16. (New) An antibody, which specifically binds to human platelet membrane glycoprotein VI (GPVI), wherein VH CDR1, VH CDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 has the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 98, SEQ ID NO: 99 and SEQ ID NO: 100, respectively; or VH CDR1, VH CDR2,

VHCDR3, VLCDR1, VLCDR2, and VLCDR3 has the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12, respectively.

17. (New) An antibody, which specifically binds to human platelet membrane glycoprotein VI (GPVI), wherein VH CDR1, VH CDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 has the amino acid sequence of SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 101, SEQ ID NO: 102 and SEQ ID NO: 103, respectively; SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 142, SEQ ID NO: 104 and SEQ ID NO: 105, respectively; SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 106, SEQ ID NO: 107 and SEQ ID NO: 108, respectively; SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 109, SEQ ID NO: 110 and SEQ ID NO: 111, respectively; SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 112, SEQ ID NO: 113 and SEQ ID NO: 114, respectively; SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 115, SEQ ID NO: 116 and SEQ ID NO: 117, respectively; SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 118, SEQ ID NO: 119 and SEQ ID NO: 120, respectively; SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 121, SEQ ID NO: 122 and SEQ ID NO: 123, respectively; SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 124, SEQ ID NO: 125 and SEQ ID NO: 126, respectively; SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 127, SEQ ID NO: 128 and SEQ ID NO: 129, respectively; SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 130, SEQ ID NO: 131 and SEQ ID NO: 132, respectively; SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 133, SEQ ID NO: 134 and SEQ ID NO: 135, respectively; SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 136, SEQ ID NO: 137 and SEQ ID NO: 138, respectively; or SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 139, SEQ ID NO: 140 and SEQ ID NO: 141, respectively.

18. (New) An antibody, which specifically binds to human platelet membrane glycoprotein VI (GPVI) and comprises SEQ ID NO: 15 within the H-chain variable region and/or

SEQ ID NO: 16 within the L-chain variable region, or which comprises SEQ ID NO: 143 within the H-chain variable region and/or SEQ ID NO: 144 within the L-chain variable region.

19. (New) A pharmaceutical composition that comprises the antibody of one of claims 12 through 18 as an active ingredient.